Oncology
Cancer treatment poses increasingly complex clinical challenges for healthcare systems across the region. At ELEA EXELTIS, we develop and offer oncology therapies aimed at different tumor types, with the goal of contributing to regional access to treatments aligned with scientific advances and modern oncology medicine.
| BRAND NAME | ACTIVE INGREDIENT | INDICATION | COMMERCIALIZATION |
|---|---|---|---|
|
Abiratex
|
Abiraterone | Metastatic high-risk hormone-sensitive prostate cancer in combination with androgen deprivation therapy. |
 
|
|
Abiratex Abiraterone Metastatic high-risk hormone-sensitive prostate cancer in combination with androgen deprivation therapy. |
|||
|
Atonox
|
Fulvestrant | Advanced or metastatic HR+ breast cancer in postmenopausal women. |
 
|
|
Atonox Fulvestrant Advanced or metastatic HR+ breast cancer in postmenopausal women. |
|||
|
Bevax
|
Bevacizumab | Advanced or metastatic tumors, including colorectal, lung, glioblastoma, ovarian, renal, and cervical cancer. |
|
|
Bevax Bevacizumab Advanced or metastatic tumors, including colorectal, lung, glioblastoma, ovarian, renal, and cervical cancer. |
|||
|
Elefix
|
Eribulin | Advanced breast cancer or liposarcoma. |
 
|
|
Elefix Eribulin Advanced breast cancer or liposarcoma. |
|||
|
Exobozan
|
cabozantinib | Advanced renal cell carcinoma or hepatocellular carcinoma as second-line treatment. |
|
|
Exobozan cabozantinib Advanced renal cell carcinoma or hepatocellular carcinoma as second-line treatment. |
|||
|
Gineva
|
Everolimus | Tumors such as HR+ breast cancer, renal cancer, TSC-related tumors, and advanced neuroendocrine tumors. |
|
|
Gineva Everolimus Tumors such as HR+ breast cancer, renal cancer, TSC-related tumors, and advanced neuroendocrine tumors. |
|||
|
Incox
|
Axitinib | Advanced renal cell carcinoma in adults. |
|
|
Incox Axitinib Advanced renal cell carcinoma in adults. |
|||
|
Ixomida
|
Apalutamide | Metastatic castration-sensitive or high-risk non-metastatic castration-resistant prostate cancer. |
|
|
Ixomida Apalutamide Metastatic castration-sensitive or high-risk non-metastatic castration-resistant prostate cancer. |
|||
|
Pembrox
|
Pembrolizumab | Immunotherapy for multiple advanced or metastatic tumors including NSCLC, renal cancer, TNBC, cervical, endometrial cancer, and melanoma. |
|
|
Pembrox Pembrolizumab Immunotherapy for multiple advanced or metastatic tumors including NSCLC, renal cancer, TNBC, cervical, endometrial cancer, and melanoma. |
|||
|
Perciclib
|
Palbociclib | Advanced HR+ HER2- breast cancer. |
|
|
Perciclib Palbociclib Advanced HR+ HER2- breast cancer. |
|||
|
Reglicat
|
Afatinib | Locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations. |
|
|
Reglicat Afatinib Locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations. |
|||
|
Terfun
|
Tipiracil + Trifluridine | Metastatic colorectal cancer refractory to prior therapies or not suitable for other available treatments. |
|
|
Terfun Tipiracil + Trifluridine Metastatic colorectal cancer refractory to prior therapies or not suitable for other available treatments. |
|||
|
Visedge
|
Vismodegib | Metastatic or locally advanced basal cell carcinoma. |
|
|
Visedge Vismodegib Metastatic or locally advanced basal cell carcinoma. |
|||
|
Zalutex
|
Enzalutamide | Advanced or metastatic prostate cancer. |
|
|
Zalutex Enzalutamide Advanced or metastatic prostate cancer. |
|||